Genmab As Stock Today
| GNMSF Stock | USD 290.34 0.67 0.23% |
Performance4 of 100
| Odds Of DistressLess than 9
|
Genmab A/S is trading at 290.34 as of the 24th of April 2024. This is a 0.23 percent up since the beginning of the trading day. The stock's lowest day price was 279.36. Genmab A/S has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Genmab AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States. The company has 65.96 M outstanding shares. More on Genmab AS
Moving together with Genmab Pink Sheet
| 0.71 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.69 | NONOF | Novo Nordisk AS | PairCorr |
Moving against Genmab Pink Sheet
| 0.56 | HNRC | Houston Natural Resources Earnings Call This Week | PairCorr |
| 0.41 | WXIBF | WuXi Biologics | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genmab Pink Sheet Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genmab A/S's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genmab A/S or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President and CEO | Jan Winkel |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Genmab AS [GNMSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab A/S's market, we take the total number of its shares issued and multiply it by Genmab A/S's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genmab A/S classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 65.96 M outstanding shares.
Genmab AS has accumulated about 21.61 B in cash with 2.23 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 330.53.
Check Genmab A/S Probability Of Bankruptcy
Ownership AllocationGenmab A/S secures a total of 65.96 Million outstanding shares. 30% of Genmab A/S outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Genmab Ownership Details
Genmab Stock Price Odds Analysis
In reference to a normal probability distribution, the odds of Genmab A/S jumping above the current price in 90 days from now is about 43.08%. The Genmab AS probability density function shows the probability of Genmab A/S pink sheet to fall within a particular range of prices over 90 days. Assuming the 90 days horizon the pink sheet has a beta coefficient of 1.0799. This usually indicates Genmab AS market returns are reactive to returns on the market. As the market goes up or down, Genmab A/S is expected to follow. Additionally, genmab AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Genmab A/S to move above the current price in 90 days from now is about 43.08 (This Genmab AS probability density function shows the probability of Genmab Pink Sheet to fall within a particular range of prices over 90 days) .
Genmab A/S Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Genmab A/S market risk premium is the additional return an investor will receive from holding Genmab A/S long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Genmab A/S. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Genmab A/S's alpha and beta are two of the key measurements used to evaluate Genmab A/S's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.55 | |||
| Semi Deviation | 2.03 | |||
| Standard Deviation | 2.06 | |||
| Variance | 4.23 |
Genmab Stock Against Markets
Picking the right benchmark for Genmab A/S pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Genmab A/S pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Genmab A/S is critical whether you are bullish or bearish towards Genmab AS at a given time. Please also check how Genmab A/S's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab A/S without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Genmab A/S Corporate Directors
Genmab A/S corporate directors refer to members of a Genmab A/S board of directors. The board of directors generally takes responsibility for the Genmab A/S's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Genmab A/S's board members must vote for the resolution. The Genmab A/S board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Daniel Bruno | Director, Employee Representative | Profile | |
| Peter Kristensen | Director, Employee Representative | Profile | |
| Nedjad Losic | Director, Employee Representative | Profile | |
| Paolo Paoletti | Director | Profile |
How to buy Genmab Pink Sheet?
Before investing in Genmab A/S, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Genmab A/S. To buy Genmab A/S stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Genmab A/S. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Genmab A/S stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Genmab AS stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Genmab AS stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Genmab AS, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Genmab Pink Sheet please use our How to Invest in Genmab A/S guide.
Already Invested in Genmab AS?
The danger of trading Genmab AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Genmab A/S is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Genmab A/S. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Genmab A/S is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab A/S's price analysis, check to measure Genmab A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab A/S is operating at the current time. Most of Genmab A/S's value examination focuses on studying past and present price action to predict the probability of Genmab A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab A/S's price. Additionally, you may evaluate how the addition of Genmab A/S to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |